Hippocratic Growth


OrbiMed Advisors' Sam Isaly, Geoff Hsu, Richard Klemm, Trevor Polischuk and Will Sawyer describe why they don’t fear binary events that other investors shun, why half their portfolio companies are likely acquisition targets, how they would simplify healthcare reform, and what they think the market is missing in Roche, Mylan, BioMarin and Illumina.

If you are a subscriber, log in to access the issue and bonus archive: